Well-Designed Bone-Seeking Radiolabeled Compounds for Diagnosis and Therapy of Bone Metastases

Table 2

Radiopharmaceuticals approved for bone metastases by FDA or EMA.

Radiopharmaceutical	Standard dose	Use
^99mTc-MDP	370–740 MBq	Diagnosis
^99mTc-HMDP	370–740 MBq	Diagnosis
NaF (IASOflu)	18.5–74 MBq	Diagnosis
^89SrCl2 (Metastron)	148 MBq; 1.5–2.2 MBq/kg	Therapy
^153Sm-EDTMP (Quadramet)	37 MBq/kg	Therapy
^223RaCl2 (Xofigo)	50 kBq/kg	Therapy